New study monitors eylea in premature Babies' eye disease
NCT ID NCT05705258
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study follows 75 Japanese babies with retinopathy of prematurity (ROP) who are being treated with Eylea, a drug injected into the eye. ROP causes abnormal blood vessel growth in the retina and can lead to blindness. The study collects real-world data on side effects and how well the drug works over 6 months. No extra tests are done beyond routine care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aflibercept (Eylea)
- What this could lead to
- If successful, this study could confirm that Eylea is a safe and effective treatment for ROP in Japanese babies, helping prevent blindness.
- What could go wrong
- This is an observational study with no control group, so results are less definitive. It only includes Japanese babies, so findings may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Many locations
Multiple Locations, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a palm oil free formula with prebiotics and postbiotics ease babies' digestion?
- Oxygen drops during eye injections in preterm babies: a hidden risk?
- Epidural analgesia in labor: could it shape your Baby's future?
- Tiny doses of avastin tested against laser for preemie eye disease
- Gene test for newborns: could it spot hidden diseases?
- Iron pills for babies: daily or weekly? new study has answers